UK Markets closed

Inhibikase Therapeutics, Inc. (IKT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.6649-0.0351 (-5.01%)
As of 11:41AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.03
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 31.5200
52-week low 30.4400
50-day moving average 30.7176
200-day moving average 30.7527

Share statistics

Avg vol (3-month) 3432.2k
Avg vol (10-day) 3604.78k
Shares outstanding 525.23M
Implied shares outstanding 6N/A
Float 817.15M
% held by insiders 125.44%
% held by institutions 123.06%
Shares short (30 Jan 2023) 4301.89k
Short ratio (30 Jan 2023) 40.53
Short % of float (30 Jan 2023) 41.33%
Short % of shares outstanding (30 Jan 2023) 41.08%
Shares short (prior month 29 Dec 2022) 4189.78k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 0.00%
Operating margin (ttm)-30,468.63%

Management effectiveness

Return on assets (ttm)-31.62%
Return on equity (ttm)-55.10%

Income statement

Revenue (ttm)61.82k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)-97.80%
Gross profit (ttm)-8.26M
Net income avi to common (ttm)-18.82M
Diluted EPS (ttm)-0.7840
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)26.53M
Total cash per share (mrq)1.05
Total debt (mrq)374.07k
Total debt/equity (mrq)1.49
Current ratio (mrq)8.71
Book value per share (mrq)1.72

Cash flow statement

Operating cash flow (ttm)-17.89M
Levered free cash flow (ttm)-11.21M